newsfilter
← Latest News
PR Newswire·

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

Results from the Phase 3 studies evaluating impact of bimekizumab on pain and health-related quality of life in moderate-to-severe hidradenitis suppurativa will be shared in two oral presentationsATLANTA, Oct. 13, 2023